PCYC Profile — Pharmacyclics, Inc.
Pharmacyclics is a biopharmaceutical company that designs, develops and commercializes therapies with a focus on product candidates that are small-molecule drugs for the treatment of cancer and immune-mediated diseases. Co.'s IMBRUVICA™ product has been developed for mantle cell lymphoma and chronic lymphocytic leukemia patients, who in each case have received at least one prior therapy. Co. also has three other product candidates in clinical development, including a Bruton's tyrosine kinase inhibitor targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa (PCI-27483), and a histone deacetylase inhibitor targeting in solid tumors and hematological malignancies.
|
|
Free PCYC Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.20 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |